- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01231308
Roux-en-Y-Gastric Bypass vs. Lifestyle Modification and Medical Therapy in the Treatment of Type 2 Diabetes
Roux-en-Y-Gastric Bypass (RYGB) Versus Lifestyle Modification Plus Medical Therapy in the Treatment of Type 2 Diabetes in Overweight-to-Moderately Obese Patients: A Randomized Clinical Trial
The study is aimed to compare: Laparoscopic Roux-en-Y-Gastric Bypass (RYGB) + optimal medical therapy versus Intensive lifestyle modification and optimal medical therapy in the treatment of type 2 diabetes in overweight-to-moderately obese patients (BMI: 28-34kg/m2; the lower BMI cut-off will be 26kg/m2 in patients of Asian descent).
This is a single center, prospective randomized study. The study at the Weill College Medical College Diabetes Surgery Center. This study is intended to be a pilot investigation whose results can inform clinicians and researchers for future larger or multi-site trials of diabetes surgery. This study will also be used for the definition of a "core" protocol for independent randomized clinical trials to be carried out at various centers participating in a multinational consortium.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Melissa Marine
- Phone Number: 212-746-5725
- Email: mem9065@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical College
-
Contact:
- Melissa Marine
- Phone Number: 212-746-5725
- Email: mem9065@med.cornell.edu
-
Principal Investigator:
- Francesco Rubino, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosed with type 2 diabetes by any of the following:
- A fasting plasma glucose > 126 mg/dl confirmed on repeated testing
- 2 hour plasma glucose > 200mg/dl during a 75 gram oral glucose tolerance test
- HbA1c >6.5%
- A normal or high C-peptide level (> 0.9 ng/ml) to exclude type 1 diabetes and insulin deficient type 2 diabetes
- Negative AntiGAD 65 Antibodies
Body mass index (BMI) between 28 and 35 kg/m2 ( > 27.6 kg/m2 and < 34.5 kg/m2 ) that reflect a condition of overweight to moderate obesity.
In consideration of the evidence that the associations between BMI, percentage of body fat, and CV risk differ across populations, and that the proportion of Asian people with a high risk of type 2 diabetes and cardiovascular disease is substantial at BMI's lower than the existing WHO cut-off point for overweight (= 25 kg/m2) (source: WHO Expert consultation. Lancet. 2004 Jan 10;363(9403):157-63), the lower BMI cut-off for inclusion in this study will be 26kg/m2 for patients of Asian descent.
- No contraindications for surgery or General Anesthesia as determined by a multidisciplinary team (surgeon, endocrinologist/internist, cardiologist, nutritionist)
- . Between 21 and 65 years of age
- . Able to provide informed consent
. If a female with reproductive potential, agreement to use a reliable method of birth control for 2 years following surgery (Barrier, birth control, patch).
This precaution is necessary to prevent potential complications of pregnancy due to possible nutritional deficiencies in the period of more intense weight loss after surgery. On the other hand, this precaution will avoid erratic weight/glucose tolerance changes of pregnancy effecting results.
- Have valid health insurance
Exclusion Criteria:
- Diagnosis of diabetes more than 15 years (to exclude pts with significant decline in pancreatic function from long-standing diabetes)
- Insulin therapy for more than 12 years
- HbA1c higher than 10%
- Diagnosis of type 1 diabetes
- Enrolled in another clinical study which involves an investigational drug
- Major psychological disorders
- Pregnancy (all female patients will have serum beta hCG) or planned pregnancy within two years of entry into the study or unwilling to use reliable contraceptive method
- Previous gastric or esophageal surgery
- Immunosuppressive drugs including corticosteroids
- Coagulopathy (INR > 1.5 or platelets < 50,000/μl)
- Anemia (Hb < 10.0 g/dl)
- Any contraindication to laparoscopic gastric bypass or medical diabetes therapy
- A severe concurrent illness likely to limit life (e.g. cancer) or requiring extensive systemic treatment (e.g. ulcerative colitis)
- A significant malabsorptive or gastrointestinal disorder (e.g. pancreatic insufficiency, Celiac sprue, or Crohn's disease)
- Significant proteinuria (> 250 mg/dl)
- Severe neuropathy or clinical diagnosis of gastropathy (early satiety, nausea, vomiting, constipation alternating with diarrhea)
- Myocardial infarction in the previous year, current angina or heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lifestyle modification
Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
|
Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content.
After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
|
Experimental: Roux-en-Y-Gastric Bypass
A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
|
Standard laparoscopic gastric bypass.
Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision.
Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary end-point will be the control of hyperglycemia (HbA1c <6.5% + FG<126mg/dl).
Time Frame: Monthly after initiation of study for a minimum of 3 months, and then every monthly until HbA1c is below 7%
|
Monthly after initiation of study for a minimum of 3 months, and then every monthly until HbA1c is below 7%
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Short (2 yrs) and long term (5 yrs.) achievement of 'adequate" glycemic control, mean change in HbA1c from baseline.
Time Frame: Year 2 and year 5
|
Year 2 and year 5
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Francesco Rubino, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1002010906
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
-
University of Alabama at BirminghamActive, not recruitingType 2 Diabetes MellitusUnited States
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... and other collaboratorsCompletedType 2 Diabetes Mellitus
Clinical Trials on Intensive lifestyle modification and Optimal medical Therapy
-
Imperial College LondonLondon North West Healthcare NHS TrustCompletedType 2 DiabetesUnited Kingdom
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedCoronary Artery DiseaseKorea, Republic of, Taiwan, Thailand, Indonesia, India
-
National Taiwan University HospitalUnknownHypertriglyceridemia During PregnancyTaiwan
-
Uptake Medical Technology, Inc.MedPass InternationalNot yet recruiting
-
Aeris TherapeuticsTerminatedPulmonary EmphysemaUnited States, Spain, France, Israel, Netherlands, Greece, Italy
-
Toad Medical CorporationUniversity Hospitals Cleveland Medical CenterUnknownDiabetic Foot | Pedal UlcersUnited States
-
Catholic University of the Sacred HeartUniversity of Roma La SapienzaCompletedNon Alcoholic SteatohepatitisItaly
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR)Active, not recruitingAtrial Fibrillation | Heart Disease | Congestive Heart FailureCanada
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); MedtronicCompletedHeart Failure, CongestiveCanada, Netherlands, Australia, Turkey, Denmark, Germany, Belgium
-
Semmelweis University Heart and Vascular CenterUnknownMyocardial Infarction | Chronic Heart FailureHungary